Search results
Showing 151 to 165 of 172 results for pembrolizumab
In development [GID-TA11345] Expected publication date: TBC
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)
This guidance has been updated and replaced by NICE technology appraisal guidance 531.
This guidance has been updated and replaced by NICE technology appraisal guidance 939.
This guidance has been updated and replaced by NICE technology appraisal guidance 692.
This guidance has been updated and replaced by NICE technology appraisal guidance 770.
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 683.
In development [GID-TA11582] Expected publication date: TBC
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
In development [GID-TA11442] Expected publication date: TBC
In development [GID-TA11466] Expected publication date: TBC
In development [GID-TA11486] Expected publication date: TBC
In development [GID-TA11401] Expected publication date: TBC
follow-up of people who received pembrolizumab as an adjuvant treatment- who develop advanced disease and receive...
For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.